Erasca, Inc. (NASDAQ:ERAS - Get Free Report) shares crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $14.89 and traded as low as $13.60. Erasca shares last traded at $13.89, with a volume of 8,789,965 shares changing hands.
Erasca News Summary
Here's some of the latest news about ERAS:
- Positive Sentiment: Erasca will collaborate with Bristol Myers Squibb on a Phase 1/2 trial of ERAS-0015 plus navlimetostat for MTAP-deleted pancreatic cancer. BMS will sponsor the study and Erasca will supply its drug, giving ERAS-0015 a major-pharma development partner without transferring either company’s rights to its compound. The combination is based on the prevalence of co-occurring RAS mutations in these tumors. Collaboration announcement
- Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $35 price target, adding to the favorable analyst view of ERAS. Price targets are opinions, not guarantees. Leerink analyst coverage
- Negative Sentiment: Earlier HC Wainwright estimates lowered projected earnings across several future periods, including a wider expected loss for 2026. The firm nevertheless maintained its Buy rating and $22 target. Erasca remains a clinical-stage company, so trial outcomes, timing, and funding needs are key uncertainties.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on ERAS. Weiss Ratings restated a "sell (d-)" rating on shares of Erasca in a research report on Tuesday, September 8th. Leerink Partners started coverage on shares of Erasca in a report on Tuesday. They set an "outperform" rating and a $35.00 price target for the company. Guggenheim raised their price objective on Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Bank of America boosted their target price on Erasca from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Finally, HC Wainwright increased their price target on shares of Erasca from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.17.
Check Out Our Latest Stock Analysis on ERAS
Erasca Stock Down 8.1%
The firm has a fifty day simple moving average of $14.89 and a 200-day simple moving average of $15.30. The company has a market cap of $4.87 billion, a PE ratio of -14.03 and a beta of 0.68.
Erasca (NASDAQ:ERAS - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Equities research analysts forecast that Erasca, Inc. will post -0.51 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Erasca
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. increased its holdings in Erasca by 1.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 24,975,188 shares of the company's stock valued at $457,545,000 after buying an additional 300,000 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Erasca in the second quarter worth $387,544,000. Vivo Capital LLC raised its stake in Erasca by 31.0% in the 1st quarter. Vivo Capital LLC now owns 12,151,480 shares of the company's stock valued at $196,611,000 after purchasing an additional 2,878,052 shares during the last quarter. Siren L.L.C. lifted its stake in shares of Erasca by 28.4% during the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company's stock valued at $181,932,000 after buying an additional 2,486,997 shares during the period. Finally, ARCH Venture Management LLC acquired a new position in Erasca in the 2nd quarter valued at $129,917,324. Institutional investors and hedge funds own 67.78% of the company's stock.
About Erasca
(
Get Free Report)
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.